Amanote Research
Register
Sign In
Hypogammaglobulinemia and Hypocomplementemia as Strong Prognostic Factors in Newly Diagnosed Diffuse Large B Cell Lymphoma
Hematological Oncology
- United Kingdom
doi 10.1002/hon.86_2631
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Hematology
Date
June 1, 2019
Authors
W. Xu
B. Pan
H. Zhu
L. Wang
L. Fan
J. Li
Publisher
Wiley
Related search
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Correlation of Pretreatment 18f-FDG Uptake With Clinicopathological Factors and Prognosis in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Nuclear Medicine Communications
Medicine
Nuclear Medicine
Radiology
Imaging
Prognostic Impact of Tumor-Associated Macrophages, Lymphocyte-To-Monocyte and Neutrophil-To-Lymphocyte Ratio in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Lenalidomide and Obinutuzumab With Chop for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I/Ii Results
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Diffuse Large B-Cell Lymphoma
Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Prognostic Significance of Serum Aspartic Transaminase in Diffuse Large B-Cell Lymphoma
BMC Cancer
Cancer Research
Oncology
Genetics
Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma
Cancer
Cancer Research
Oncology
Secondary Cutaneous Diffuse Large B-Cell Lymphoma Has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-Cell Lymphoma, Leg Type
Acta Dermato-Venereologica
Dermatology
Medicine
